Abstract
CD26 is a widely expressed transmembrane glycoprotein with peptidase activity in its extracellular domain and which regulates multiple biological processes. It acts mainly as catabolic enzyme for a number of circulating proteins involved in common pathological conditions such as diabetes and cardiovascular disease and may represent a target to modulate bioavailability of crucial substrates. The aim of the present review is to summarize data regarding CD26-based pharmacological interventions. Four main subtopics were identified:1) CD26 as the target of pharmacological inhibitors to increase bioavailability of glucagon-like petide-1 (GLP-1) and hence to enhance GLP-1 glucose-lowering activity in diabetic patients; 2) role of CD26 in the physiology and pathology of the cardiovascular system; 3) the adverse prognostic value of CD26 expression on cancer cells; 4) CD26 down-regulation on lymphocytes as a mechanism of TGF-beta immunomodulation.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 157-164 |
| Numero di pagine | 8 |
| Rivista | Current Clinical Pharmacology |
| Volume | 9 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2014 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
Keywords
- Animals
- Cardiovascular Diseases
- Diabetes Mellitus
- Dipeptidyl Peptidase 4
- Dipeptidyl-Peptidase IV Inhibitors
- Glucagon-Like Peptide 1
- Humans
- Molecular Targeted Therapy
- Neoplasms
Fingerprint
Entra nei temi di ricerca di 'CD26: a multi-purpose pharmacological target'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver